Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype-Reference-Cited by-同舟云学术

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype

Published:2019-01-24 Issue: Volume:12 Page:
ISSN:1662-5099
Container-title:Frontiers in Molecular Neuroscience
language:
Short-container-title:Front. Mol. Neurosci.

Author:

Sala Luca,Cirillo Giovanni,Riva Gabriele,Romano Gabriele,Giussani Carlo,Cialdella Annamaria,Todisco Antonio,Virtuoso Assunta,Cerrito Maria Grazia,Bentivegna Angela,Grassilli Emanuela,Ardizzoia Antonio,Bonoldi Emanuela,Giovannoni Roberto,Papa Michele,Lavitrano Marialuisa

Publisher

Frontiers Media SA

Subject

Cellular and Molecular Neuroscience,Molecular Biology

Reference27 articles.

1. Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations—a study of 32 cases;Avninder;J. Neurooncol.,2006

2. Low-grade astrocytomas: the prognostic value of fibrillary, gemistocytic, and protoplasmic tumor histology;Babu;J. Neurosurg.,2013

3. Delineating the cytogenomic and epigenomic landscapes of glioma stem cell lines;Baronchelli;PLoS One,2013

4. Resveratrol impairs glioma stem cells proliferation and motility by modulating the Wnt signaling pathway;Cilibrasi;PLoS One,2017

5. p65BTK is a novel therapeutic target in ovarian cancer;Conconi,2017

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BTK Isoforms p80 and p65 Are Expressed in Head and Neck Squamous Cell Carcinoma (HNSCC) and Involved in Tumor Progression;Cancers;2023-01-03

2. BTK is a Prognostic Biomarker for Multiple Human Tumors;2022-11-30

3. Bruton’s Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis;Journal of Clinical Medicine;2022-10-18

4. Tumor Microenvironment and Immune Escape in the Time Course of Glioblastoma;Molecular Neurobiology;2022-09-01

5. BTK, the new kid on the (oncology) block?;Frontiers in Oncology;2022-08-04